DK2508621T3 - Optimering og individualisering af valg og dosering af medikamenter - Google Patents
Optimering og individualisering af valg og dosering af medikamenter Download PDFInfo
- Publication number
- DK2508621T3 DK2508621T3 DK11185491.5T DK11185491T DK2508621T3 DK 2508621 T3 DK2508621 T3 DK 2508621T3 DK 11185491 T DK11185491 T DK 11185491T DK 2508621 T3 DK2508621 T3 DK 2508621T3
- Authority
- DK
- Denmark
- Prior art keywords
- drug
- patient
- functional
- dose
- specific
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Primary Health Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Artificial Intelligence (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
Claims (2)
1. Fremgangsmåde til bestemmelse af en startdosis af et etneuropsykiatrisk lægemiddel til indgivelse til en patient med behov herfor, hvilken fremgangsmåde omfatter (a) modtagelse af den normale lægemiddeldosis til populationen, som repræsenterer patienten (Dpop), på en processor; (b) modtagelse af patientens genotype for et panel af gener på en processor omfattende følgende cytochrom P450 (CYP) gener: CYP2D6, CYP2C19 og CYP2C9; (c) bestemmelse af antallet af funktionelle og ikke-funktionelle alleler for hvert gen på basis af genotypen; (d) placering af patienten i en metabolisme-fænotype-undergruppe på basis af antallet af funktionelle alleler for hvert af CYP-generne, hvor metabolismeundergruppen udvælges fra en af følgende: ekstensiv metabolisme (EM) = 2 funktionelle alleler, intermediær metabolisme (IM) = 1 funktionel allel og langsom metabolisme (PM) = 0 funktionelle alleler; (e) modtagelse af frekvensen af metabolisme-fænotype-undergrupperne i populationen på en processor; og (f) via en processor bestemmelse af startdosen af lægemidlet eksprimeret som en procentdel på basis af antallet af ikke-funktionelle alleler som følger: procentvis reduktion for en ikke-funktionel allel: (DRem% - DR!m%)/ DRem% procentvis reduktion for to ikke-funktionelle alleler: (DRem% - DRpM%)/ DRkm% hvor DRX% er dosisanbefalingen for metabolisme-undergruppen X eksprimeret som en procentdel af den normale lægemiddeldosis (DpoP), hvor Dpop = fpM(DpM) + fiM(Dim) + ίεινιφΕΜ), og hvor Dem reduceres med 20 % for hver ikke-funktionel CYP2D6 eller CYP2C19 allel og med 40 % for hver ikke-funktionel CYP2C9 allel.
2. Fremgangsmåde ifølge krav 1, hvorved den normale lægemiddeldosis (Dpop) reduceres med 20 % for hver ikke-funktionel CYP2D6 allel, som detekteres i patienten, og lægemidlet udvælges fra gruppen bestående af atomoxetin, imipramin, perp- henazin, doxepin, maprotilin, trimipramin, thioridazin, desipramin, clomipramin, zuclopenthixol, paroxetin, venlafaxin, flupentixol og mianserin; 20 % for hver ikke-funktionel CYP2C19 allel, der detekteres i patienten, og lægemidlet udvælges fra gruppen bestående af trimipramin, amitryptilin, moclobemid, imipramin, citalopram, clomipramin og fluoxetin; og 40 % for hver ikke-funktionel CYP2C9 allel, der detekteres i patienten, og lægemidlet udvælges fra gruppen bestående af amaryl, glipizid, diabeta, glu-covance, cozaar, hyzaar, diabinese, orinase, tolinase og warfarin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74043005P | 2005-11-29 | 2005-11-29 | |
US78311806P | 2006-03-16 | 2006-03-16 | |
EP06838538A EP1958111A4 (en) | 2005-11-29 | 2006-11-28 | OPTIMIZATION AND PERSONALIZATION OF SELECTION AND DOSAGE OF DRUGS |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2508621T3 true DK2508621T3 (da) | 2015-01-12 |
Family
ID=38092744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11185491.5T DK2508621T3 (da) | 2005-11-29 | 2006-11-28 | Optimering og individualisering af valg og dosering af medikamenter |
Country Status (9)
Country | Link |
---|---|
US (4) | US8589175B2 (da) |
EP (4) | EP3703058A1 (da) |
JP (4) | JP2009517186A (da) |
AU (1) | AU2006320633A1 (da) |
CA (3) | CA2911569C (da) |
DK (1) | DK2508621T3 (da) |
ES (1) | ES2529211T3 (da) |
HK (2) | HK1176093A1 (da) |
WO (1) | WO2007064675A2 (da) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
ES2575903T3 (es) | 2003-02-20 | 2016-07-04 | Mayo Foundation For Medical Education And Research | Métodos para seleccionar medicamentos antidepresivos |
US8688385B2 (en) * | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
CA2911569C (en) * | 2005-11-29 | 2019-11-26 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
GB2462218A (en) * | 2006-03-10 | 2010-02-03 | Neurotech Res Pty Ltd | Subject modelling |
US8099298B2 (en) * | 2007-02-14 | 2012-01-17 | Genelex, Inc | Genetic data analysis and database tools |
US8732188B2 (en) * | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
JP4882927B2 (ja) * | 2007-08-31 | 2012-02-22 | セイコーエプソン株式会社 | カテゴリ識別方法 |
JP2009093334A (ja) * | 2007-10-05 | 2009-04-30 | Seiko Epson Corp | 識別方法及びプログラム |
CN101965514A (zh) * | 2008-01-03 | 2011-02-02 | 艾博特生物技术有限公司 | 预测化合物在治疗银屑病中的长期功效 |
US20090216561A1 (en) * | 2008-02-22 | 2009-08-27 | Swedish Health Services | Methods for management of anticoagulation therapy |
US20090216639A1 (en) * | 2008-02-25 | 2009-08-27 | Mark Joseph Kapczynski | Advertising selection and display based on electronic profile information |
US20090216563A1 (en) * | 2008-02-25 | 2009-08-27 | Michael Sandoval | Electronic profile development, storage, use and systems for taking action based thereon |
US9026369B2 (en) * | 2008-04-24 | 2015-05-05 | The Invention Science Fund I, Llc | Methods and systems for presenting a combination treatment |
US8682687B2 (en) * | 2008-04-24 | 2014-03-25 | The Invention Science Fund I, Llc | Methods and systems for presenting a combination treatment |
US8930208B2 (en) | 2008-04-24 | 2015-01-06 | The Invention Science Fund I, Llc | Methods and systems for detecting a bioactive agent effect |
US9649469B2 (en) | 2008-04-24 | 2017-05-16 | The Invention Science Fund I Llc | Methods and systems for presenting a combination treatment |
US20090270687A1 (en) * | 2008-04-24 | 2009-10-29 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for modifying bioactive agent use |
US20100030089A1 (en) * | 2008-04-24 | 2010-02-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for monitoring and modifying a combination treatment |
US20100076249A1 (en) * | 2008-04-24 | 2010-03-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational system and method for memory modification |
US20100280332A1 (en) * | 2008-04-24 | 2010-11-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for monitoring bioactive agent use |
US8615407B2 (en) * | 2008-04-24 | 2013-12-24 | The Invention Science Fund I, Llc | Methods and systems for detecting a bioactive agent effect |
US9282927B2 (en) * | 2008-04-24 | 2016-03-15 | Invention Science Fund I, Llc | Methods and systems for modifying bioactive agent use |
US9449150B2 (en) * | 2008-04-24 | 2016-09-20 | The Invention Science Fund I, Llc | Combination treatment selection methods and systems |
US20100042578A1 (en) * | 2008-04-24 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational system and method for memory modification |
US9560967B2 (en) * | 2008-04-24 | 2017-02-07 | The Invention Science Fund I Llc | Systems and apparatus for measuring a bioactive agent effect |
US20100081860A1 (en) * | 2008-04-24 | 2010-04-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational System and Method for Memory Modification |
US8606592B2 (en) * | 2008-04-24 | 2013-12-10 | The Invention Science Fund I, Llc | Methods and systems for monitoring bioactive agent use |
US8876688B2 (en) | 2008-04-24 | 2014-11-04 | The Invention Science Fund I, Llc | Combination treatment modification methods and systems |
US7974787B2 (en) * | 2008-04-24 | 2011-07-05 | The Invention Science Fund I, Llc | Combination treatment alteration methods and systems |
US20090271122A1 (en) * | 2008-04-24 | 2009-10-29 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for monitoring and modifying a combination treatment |
US20100004762A1 (en) * | 2008-04-24 | 2010-01-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational system and method for memory modification |
US9662391B2 (en) * | 2008-04-24 | 2017-05-30 | The Invention Science Fund I Llc | Side effect ameliorating combination therapeutic products and systems |
US9239906B2 (en) | 2008-04-24 | 2016-01-19 | The Invention Science Fund I, Llc | Combination treatment selection methods and systems |
US9064036B2 (en) | 2008-04-24 | 2015-06-23 | The Invention Science Fund I, Llc | Methods and systems for monitoring bioactive agent use |
US20100125782A1 (en) * | 2008-11-14 | 2010-05-20 | Howard Jay Snortland | Electronic document for automatically determining a dosage for a treatment |
US20100125421A1 (en) * | 2008-11-14 | 2010-05-20 | Howard Jay Snortland | System and method for determining a dosage for a treatment |
US8122820B2 (en) * | 2008-12-19 | 2012-02-28 | Whirlpool Corporation | Food processor with dicing tool |
US10853900B2 (en) * | 2009-02-09 | 2020-12-01 | Fair Isaac Corporation | Method and system for predicting adherence to a treatment |
CN102473202B (zh) * | 2009-07-08 | 2015-11-25 | 环球创新网络公司 | 用于预测药物在患者中的疗效的方法 |
US8909593B2 (en) * | 2009-07-10 | 2014-12-09 | Medimpact Healthcare Systems, Inc. | Modifying a patient adherence score |
US8417660B2 (en) * | 2009-07-10 | 2013-04-09 | Medimpact Healthcare Systems, Inc. | Modifying a patient adherence score |
US20110082867A1 (en) * | 2009-10-06 | 2011-04-07 | NeX Step, Inc. | System, method, and computer program product for analyzing drug interactions |
JP5562209B2 (ja) * | 2009-11-04 | 2014-07-30 | 第一三共株式会社 | 医薬の観察研究又は疫学研究のための被験者登録方法 |
US20110209065A1 (en) * | 2010-02-23 | 2011-08-25 | Farmacia Electronica, Inc. | Method and system for consumer-specific communication based on cultural normalization techniques |
CN102971738A (zh) | 2010-05-06 | 2013-03-13 | 水宙责任有限公司 | 用于配置文件利用系统中的安全性的系统、方法和计算机可读介质 |
BR112013003331A2 (pt) * | 2010-08-13 | 2017-07-11 | l kraft Daniel | sistemas e métodos para a produção de produtos de fármacos personalizados |
US20120179481A1 (en) * | 2011-01-10 | 2012-07-12 | Medimpact Healthcare Systems, Inc. | Recommending Prescription Information |
US8676607B2 (en) | 2011-01-10 | 2014-03-18 | Medimpact Healthcare Systems, Inc. | Obtaining patient survey results |
US20140349862A1 (en) * | 2011-05-30 | 2014-11-27 | Vuong Ngoc Trieu | Methods and compositions for therapeutic drug monitoring and dosing by point of care pharmacokinetic profiling |
KR101289307B1 (ko) | 2011-08-23 | 2013-07-24 | 주식회사 아리바이오 | 개인별 맞춤 영양제 조제 시스템 |
WO2013036836A2 (en) * | 2011-09-08 | 2013-03-14 | Fresenius Medical Care Holdings, Inc. | System and method of modeling erythropoiesis and its management |
US20130268290A1 (en) * | 2012-04-02 | 2013-10-10 | David Jackson | Systems and methods for disease knowledge modeling |
US9940434B2 (en) | 2012-09-27 | 2018-04-10 | The Children's Mercy Hospital | System for genome analysis and genetic disease diagnosis |
KR102370479B1 (ko) * | 2012-10-05 | 2022-03-04 | 다이앤 몰드 | 수학적 모형 함수로서의 환자-특이적 투여법용 의약 |
US20140114676A1 (en) * | 2012-10-23 | 2014-04-24 | Theranos, Inc. | Drug Monitoring and Regulation Systems and Methods |
US9679111B2 (en) | 2012-11-05 | 2017-06-13 | Fresenius Medical Care Holdings, Inc. | System and method of modeling erythropoiesis including iron homeostasis |
WO2014113204A1 (en) | 2013-01-17 | 2014-07-24 | Personalis, Inc. | Methods and systems for genetic analysis |
WO2014116276A1 (en) * | 2013-01-24 | 2014-07-31 | Kantrack Llc | Individualized medicine system |
KR20150113113A (ko) | 2013-01-29 | 2015-10-07 | 몰레큘러 헬스 게엠베하 | 임상적 판단 지원을 위한 시스템 및 방법 |
US20160335412A1 (en) * | 2013-01-30 | 2016-11-17 | Geoffrey Tucker | Systems and methods for predicting and adjusting the dosage of medicines in individual patients |
US10210312B2 (en) * | 2013-02-03 | 2019-02-19 | Youscript Inc. | Systems and methods for quantification and presentation of medical risk arising from unknown factors |
WO2014121257A1 (en) * | 2013-02-04 | 2014-08-07 | Sano Informed Prescribing, Llc | Prescription decision support system and method using comprehensive multiplex drug monitoring |
US10262112B2 (en) | 2013-02-04 | 2019-04-16 | Precera Bioscience, Inc. | Prescription decision support system and method using comprehensive multiplex drug monitoring |
US20140244556A1 (en) * | 2013-02-27 | 2014-08-28 | Abdul Saleh | Methods for and apparatus generating automated pharmaco genetics correlation |
US20140274763A1 (en) * | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to pain treatments |
WO2014194410A1 (en) * | 2013-06-06 | 2014-12-11 | Timeless Technologies (2007) Inc. | Method and system for providing a treatment protocol |
WO2015006033A1 (en) * | 2013-06-20 | 2015-01-15 | Baxter International Inc. | Providing a pharmacokinetic drug dosing regime |
US20150039331A1 (en) * | 2013-08-02 | 2015-02-05 | Real Endpoints LLC | Assessing pharmaceuticals |
US20150039325A1 (en) * | 2013-08-02 | 2015-02-05 | Real Endpoints LLC | Assessing Pharmaceuticals |
EP3965111A1 (en) | 2013-08-30 | 2022-03-09 | Personalis, Inc. | Methods and systems for genomic analysis |
GB2535066A (en) | 2013-10-03 | 2016-08-10 | Personalis Inc | Methods for analyzing genotypes |
US20160239636A1 (en) * | 2013-10-07 | 2016-08-18 | The University Of Chicago | Genomic prescribing system and methods |
US20150127372A1 (en) * | 2013-11-07 | 2015-05-07 | Quintiles Transnational Corporation | Electrical Computing Devices Providing Personalized Patient Drug Dosing Regimens |
EP3080738A1 (en) * | 2013-12-12 | 2016-10-19 | AB-Biotics S.A. | Web-based computer-aided method and system for providing personalized recommendations about drug use, and a computer-readable medium |
US20150269355A1 (en) * | 2014-03-19 | 2015-09-24 | Peach Intellihealth, Inc. | Managing allocation of health-related expertise and resources |
US20150265628A1 (en) * | 2014-03-21 | 2015-09-24 | CompanionDx Reference Lab, LLC | Genomic testing for effective therapies and determination of dosing strategy |
US20170177834A1 (en) * | 2014-03-21 | 2017-06-22 | The Regents Of The University Of California | Nanomedicine optimization with feedback system control |
NZ730560A (en) * | 2014-09-29 | 2020-05-29 | Zogenix International Ltd | Control system for control of distribution of medication |
WO2016070131A1 (en) | 2014-10-30 | 2016-05-06 | Personalis, Inc. | Methods for using mosaicism in nucleic acids sampled distal to their origin |
US10534895B2 (en) | 2015-01-20 | 2020-01-14 | Icpd Technologies, Llc | System and method for ranking options for medical treatments |
WO2016147276A1 (ja) * | 2015-03-13 | 2016-09-22 | 株式会社Ubic | データ分析システム及びデータ分析方法並びにデータ分析プログラム |
AU2016245862A1 (en) * | 2015-04-09 | 2018-02-22 | Diane R. Mould | Systems and methods for patient-specific dosing |
KR101990951B1 (ko) * | 2015-04-27 | 2019-06-20 | 주식회사 네비팜 | 리바스티그민 함유 서방출 의약조성물 |
US10395759B2 (en) | 2015-05-18 | 2019-08-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for copy number variant detection |
US20180358129A1 (en) * | 2015-11-26 | 2018-12-13 | Koninklijke Philips N.V. | System and method for educating a user about a condition of interest |
US20170174614A1 (en) | 2015-12-22 | 2017-06-22 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
IL286391B (en) | 2015-12-22 | 2022-08-01 | Zogenix International Ltd | Penfluramine preparations and methods for their preparation |
US11217334B2 (en) | 2016-02-29 | 2022-01-04 | Mor Research Applications Ltd. | System and method for selecting optimal medications for a specific patient |
EP3223181B1 (en) | 2016-03-24 | 2019-12-18 | Sofradim Production | System and method of generating a model and simulating an effect on a surgical repair site |
US10436771B2 (en) * | 2016-04-05 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for targeted therapy based on single-cell stimulus perturbation response |
EP4343774A2 (en) | 2016-04-15 | 2024-03-27 | Takeda Pharmaceutical Company Limited | Method and apparatus for providing a pharmacokinetic drug dosing regiment |
WO2017202786A1 (en) * | 2016-05-25 | 2017-11-30 | F. Hoffmann-La Roche Ag | Materials and methods relating to dosage regimen design |
US11299783B2 (en) | 2016-05-27 | 2022-04-12 | Personalis, Inc. | Methods and systems for genetic analysis |
EP4201427A1 (en) | 2016-08-24 | 2023-06-28 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
US10783997B2 (en) * | 2016-08-26 | 2020-09-22 | International Business Machines Corporation | Personalized tolerance prediction of adverse drug events |
MX2019002731A (es) | 2016-09-08 | 2019-10-02 | Curematch Inc | Optimizacion de opciones terapeuticas en medicina perzonalizada. |
US20180121616A1 (en) * | 2016-10-28 | 2018-05-03 | Pinscriptive, Inc. | Systems and Methods for Treatment Decisions |
US20180121617A1 (en) * | 2016-10-28 | 2018-05-03 | Pinscriptive, Inc. | Treatment Decision Interface Device and Graphical User Interface (GUI) |
US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
JP2018156149A (ja) * | 2017-03-15 | 2018-10-04 | オムロン株式会社 | 投薬支援装置、方法およびプログラム |
CN111742370A (zh) * | 2017-05-12 | 2020-10-02 | 密歇根大学董事会 | 个体和队列药理学表型预测平台 |
CN107273710A (zh) * | 2017-08-22 | 2017-10-20 | 北京岙特杰诺生物科技有限公司 | 一种建立药物代谢酶基因与药物代谢的关系模型的方法 |
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
US11153156B2 (en) | 2017-11-03 | 2021-10-19 | Vignet Incorporated | Achieving personalized outcomes with digital therapeutic applications |
US10854326B2 (en) | 2017-11-21 | 2020-12-01 | Verisim Life Inc. | Systems and methods for full body circulation and drug concentration prediction |
AU2018392922B2 (en) | 2017-12-21 | 2021-07-01 | Aseko, Inc. | Advising diabetes medications |
US11227692B2 (en) | 2017-12-28 | 2022-01-18 | International Business Machines Corporation | Neuron model simulation |
WO2019195733A1 (en) * | 2018-04-05 | 2019-10-10 | University Of Maryland, Baltimore | Method and apparatus for individualized administration of medicaments for delivery within a therapeutic range |
WO2019209845A1 (en) * | 2018-04-23 | 2019-10-31 | Mould Diane R | Systems and methods for modifying adaptive dosing regimens |
EP3790537A1 (en) | 2018-05-11 | 2021-03-17 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
US10801064B2 (en) | 2018-05-31 | 2020-10-13 | Personalis, Inc. | Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples |
US11814750B2 (en) | 2018-05-31 | 2023-11-14 | Personalis, Inc. | Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples |
BR112020024917A2 (pt) * | 2018-06-06 | 2021-03-09 | Minoryx Therapeutics S.L. | Método de administrar uma quantidade terapeuticamente eficaz de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona |
RU2695820C1 (ru) * | 2018-09-28 | 2019-07-29 | Государственное бюджетное учреждение здравоохранения города Москвы "Московский научно-практический центр наркологии Департамента здравоохранения города Москвы" (ГБУЗ "МНПЦ наркологии ДЗМ") | Способ прогнозирования оценки эффективности терапии трифлуоперазином для лечения расстройств, сопровождающихся развитием психотической симптоматики |
US11965206B2 (en) | 2018-12-21 | 2024-04-23 | John Stoddard | Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes |
US11809382B2 (en) | 2019-04-01 | 2023-11-07 | Nutanix, Inc. | System and method for supporting versioned objects |
AU2020279079A1 (en) * | 2019-05-21 | 2022-01-20 | Syqe Medical Ltd. | Substance delivery planning system |
US11676727B2 (en) | 2019-08-14 | 2023-06-13 | Optum Technology, Inc. | Cohort-based predictive data analysis |
IT201900024150A1 (it) | 2019-12-16 | 2021-06-16 | Persongene Srl | Sistema e metodo per la determinazione di un parametro di adeguatezza di un farmaco in funzione di fattori genetici |
US11443854B2 (en) * | 2020-02-24 | 2022-09-13 | International Business Machines Corporation | Identifying potential medicinal interactions for online clinical trial study groups |
CN111696678B (zh) * | 2020-06-15 | 2023-05-26 | 中南大学 | 一种基于深度学习的用药决策方法和系统 |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
US11056242B1 (en) | 2020-08-05 | 2021-07-06 | Vignet Incorporated | Predictive analysis and interventions to limit disease exposure |
US11127506B1 (en) | 2020-08-05 | 2021-09-21 | Vignet Incorporated | Digital health tools to predict and prevent disease transmission |
US11504011B1 (en) | 2020-08-05 | 2022-11-22 | Vignet Incorporated | Early detection and prevention of infectious disease transmission using location data and geofencing |
US11456080B1 (en) | 2020-08-05 | 2022-09-27 | Vignet Incorporated | Adjusting disease data collection to provide high-quality health data to meet needs of different communities |
CN112221023B (zh) * | 2020-09-27 | 2023-12-15 | 中国辐射防护研究院 | 一种放射性药物的剂量评估系统及方法 |
US11900164B2 (en) | 2020-11-24 | 2024-02-13 | Nutanix, Inc. | Intelligent query planning for metric gateway |
US11822370B2 (en) | 2020-11-26 | 2023-11-21 | Nutanix, Inc. | Concurrent multiprotocol access to an object storage system |
TWI775253B (zh) * | 2020-12-24 | 2022-08-21 | 宏碁股份有限公司 | 高風險用藥路徑的計算方法 |
US11586524B1 (en) | 2021-04-16 | 2023-02-21 | Vignet Incorporated | Assisting researchers to identify opportunities for new sub-studies in digital health research and decentralized clinical trials |
US11789837B1 (en) | 2021-02-03 | 2023-10-17 | Vignet Incorporated | Adaptive data collection in clinical trials to increase the likelihood of on-time completion of a trial |
US11281553B1 (en) | 2021-04-16 | 2022-03-22 | Vignet Incorporated | Digital systems for enrolling participants in health research and decentralized clinical trials |
CN113345600B (zh) * | 2021-05-06 | 2024-02-27 | 中国食品药品检定研究院 | 一种抗感染药物注射剂的有效性评价方法及其应用 |
CN113917025A (zh) * | 2021-10-09 | 2022-01-11 | 上海市精神卫生中心(上海市心理咨询培训中心) | 一种定量检测生物样本中精神类药物的试剂盒及其应用 |
US11705230B1 (en) | 2021-11-30 | 2023-07-18 | Vignet Incorporated | Assessing health risks using genetic, epigenetic, and phenotypic data sources |
US11901083B1 (en) | 2021-11-30 | 2024-02-13 | Vignet Incorporated | Using genetic and phenotypic data sets for drug discovery clinical trials |
WO2023172522A1 (en) * | 2022-03-07 | 2023-09-14 | The Regents Of The University Of California | Wearable aptamer microneedle patch for continuous minimally-invasive biomonitoring |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5844108A (en) * | 1990-06-22 | 1998-12-01 | Roche Molecular Systems, Inc. | Primers targeted to NAT2 gene for detection of poor metabolizers of drugs |
DE69126064T2 (de) * | 1990-06-22 | 1997-08-28 | Hoffmann La Roche | Nachweis von schwachen Metabolisierungsreagentien von Drogen |
FI92241C (fi) | 1993-01-28 | 1994-10-10 | Sampower Oy | Menetelmä vapaamäntämoottorin tärinän vaimentamiseksi ja tärinävaimennettu vapaamäntämoottori |
US5833599A (en) * | 1993-12-13 | 1998-11-10 | Multum Information Services | Providing patient-specific drug information |
US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
WO1998047087A1 (en) * | 1997-04-17 | 1998-10-22 | Glaxo Group Ltd. | Statistical deconvoluting of mixtures |
US6251587B1 (en) * | 1997-12-16 | 2001-06-26 | Nova Molecular, Inc. | Method for determining the prognosis of a patient with a neurological disease |
WO1999042619A2 (en) * | 1998-02-20 | 1999-08-26 | City Of Hope | Association of the serotonin transport (htt) gene with cardiovascular disease and longevity |
US6081786A (en) * | 1998-04-03 | 2000-06-27 | Triangle Pharmaceuticals, Inc. | Systems, methods and computer program products for guiding the selection of therapeutic treatment regimens |
AU4529299A (en) * | 1998-06-16 | 2000-01-05 | Variagenics, Inc. | Methods for treating a neurological disease by determining bche genotype |
WO2000020634A1 (en) * | 1998-10-01 | 2000-04-13 | Nova Molecular, Inc. | Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele |
US6183963B1 (en) * | 1998-10-23 | 2001-02-06 | Signalgene | Detection of CYP1A1, CYP3A4, CYP2D6 and NAT2 variants by PCR-allele-specific oligonucleotide (ASO) assay |
US6472421B1 (en) * | 1998-11-13 | 2002-10-29 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor |
US6861217B1 (en) * | 1998-11-25 | 2005-03-01 | Genaissance Pharmaceuticals, Inc. | Variation in drug response related to polymorphisms in the β2-adrenergic receptor |
EP1218536A2 (en) * | 1999-02-12 | 2002-07-03 | Genset | Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism |
AU3997300A (en) | 1999-02-22 | 2000-09-14 | Variagenics, Inc. | Gene sequence variations with utility in determining the treatment of disease |
GB9904585D0 (en) * | 1999-02-26 | 1999-04-21 | Gemini Research Limited | Clinical and diagnostic database |
JP3777858B2 (ja) * | 1999-03-09 | 2006-05-24 | 株式会社エスアールエル | 副甲状腺ホルモン受容体遺伝子の多型性によるpth反応性予測方法 |
US6528260B1 (en) * | 1999-03-25 | 2003-03-04 | Genset, S.A. | Biallelic markers related to genes involved in drug metabolism |
US20010034023A1 (en) * | 1999-04-26 | 2001-10-25 | Stanton Vincent P. | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
EP1182266A4 (en) * | 1999-04-28 | 2002-07-24 | Sumitomo Pharma | DETERMINATION PROCEDURE FOR THE CYP2A6 GENE |
DE60036750T2 (de) * | 1999-05-18 | 2008-08-28 | Nipro Corp. | Verfahren zur Abschätzung der Sensitivität für Osteoporose-Medikamente |
US6912492B1 (en) * | 1999-05-25 | 2005-06-28 | University Of Medicine & Dentistry Of New Jersey | Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors |
US6297014B1 (en) * | 1999-07-02 | 2001-10-02 | Cedars-Sinai Medical Center | Genetic test to determine non-responsiveness to statin drug treatment |
US6338039B1 (en) * | 1999-07-20 | 2002-01-08 | Michael Lonski | Method for automated collection of psychotherapy patient information and generating reports and treatment plans |
US20020077756A1 (en) * | 1999-11-29 | 2002-06-20 | Scott Arouh | Neural-network-based identification, and application, of genomic information practically relevant to diverse biological and sociological problems, including drug dosage estimation |
GB0000896D0 (en) * | 2000-01-14 | 2000-03-08 | Univ Glasgow | Improved analytical chip |
EP1248832A4 (en) * | 2000-01-21 | 2004-07-07 | Variagenics Inc | IDENTIFICATION OF GENETIC COMPONENTS IN DRUG REACTION |
US6675166B2 (en) | 2000-02-09 | 2004-01-06 | The John Hopkins University | Integrated multidimensional database |
AU2001260224A1 (en) * | 2000-04-18 | 2001-10-30 | Virco Bvba | Methods for measuring drug resistance |
US6251608B1 (en) * | 2000-04-20 | 2001-06-26 | Technion Research & Development Foundation, Ltd. | Method of determining a potential of a hyperglycemic patients of developing vascular complications |
US20020052761A1 (en) * | 2000-05-11 | 2002-05-02 | Fey Christopher T. | Method and system for genetic screening data collection, analysis, report generation and access |
US20020010552A1 (en) * | 2000-05-26 | 2002-01-24 | Hugh Rienhoff | System for genetically characterizing an individual for evaluation using genetic and phenotypic variation over a wide area network |
US20020076774A1 (en) * | 2000-06-21 | 2002-06-20 | Chunhua Yan | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
JP2002024385A (ja) | 2000-06-30 | 2002-01-25 | Coreflow Technologies:Kk | 遺伝子情報管理システム及びその管理方法 |
CA2414403A1 (en) * | 2000-07-06 | 2002-01-17 | The Regents Of The University Of California | Methods for diagnosis and treatment of psychiatric disorders |
US6461902B1 (en) * | 2000-07-18 | 2002-10-08 | Institute Of Microelectronics | RF LDMOS on partial SOI substrate |
WO2002012434A2 (en) | 2000-08-10 | 2002-02-14 | Glaxo Group Limited | A global electronic medicine response profile testing network |
US20020091680A1 (en) * | 2000-08-28 | 2002-07-11 | Chirstos Hatzis | Knowledge pattern integration system |
US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
AU2001275020A1 (en) * | 2000-09-21 | 2002-04-02 | Theradoc.Com, Inc. | Systems and methods for manipulating medical data via a decision support system |
US20020098498A1 (en) * | 2000-09-29 | 2002-07-25 | Bader Joel S. | Method of identifying genetic regions associated with disease and predicting responsiveness to therapeutic agents |
US20050060102A1 (en) * | 2000-10-12 | 2005-03-17 | O'reilly David J. | Interactive correlation of compound information and genomic information |
US6450956B1 (en) * | 2000-11-06 | 2002-09-17 | Siemens Corporate Research, Inc. | System and method for treatment and outcome measurement analysis |
JP2002197189A (ja) | 2000-12-26 | 2002-07-12 | Sanyo Electric Co Ltd | 薬品テーラーメイドシステム |
US20020082869A1 (en) * | 2000-12-27 | 2002-06-27 | Gateway, Inc. | Method and system for providing and updating customized health care information based on an individual's genome |
US6399310B1 (en) * | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
JP2002245171A (ja) | 2001-02-13 | 2002-08-30 | Canon Sales Co Inc | 医療情報管理装置、その方法、プログラム、記憶媒体 |
US6828103B2 (en) * | 2001-02-22 | 2004-12-07 | Wake Forest University | Genetic polymorphisms of estrogen receptor alpha associated with favorable response to hormone replacement therapy |
AU2002244568A1 (en) * | 2001-03-14 | 2002-09-24 | Mcgill University | Individualization of therapy with antipsychotics |
US20020187483A1 (en) * | 2001-04-20 | 2002-12-12 | Cerner Corporation | Computer system for providing information about the risk of an atypical clinical event based upon genetic information |
WO2003008637A2 (en) | 2001-07-17 | 2003-01-30 | Xanthus Life Sciences, Inc. | Use of genotyping in the individualization of therapy |
JP2003068878A (ja) * | 2001-08-23 | 2003-03-07 | Hitachi Ltd | 半導体集積回路装置およびその製造方法 |
US7529685B2 (en) * | 2001-08-28 | 2009-05-05 | Md Datacor, Inc. | System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data |
US7461006B2 (en) * | 2001-08-29 | 2008-12-02 | Victor Gogolak | Method and system for the analysis and association of patient-specific and population-based genomic data with drug safety adverse event data |
US20030105596A1 (en) * | 2001-10-29 | 2003-06-05 | Goldstein David Benjamin | Methods for evaluating responses of a group of test subjects to a drug or other clinical treatment and for predicting responses in other subjects |
US20030104453A1 (en) * | 2001-11-06 | 2003-06-05 | David Pickar | System for pharmacogenetics of adverse drug events |
US20030157110A1 (en) * | 2002-01-07 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of metabolic disorders, including obesity and diabetes |
US20030204415A1 (en) * | 2002-04-30 | 2003-10-30 | Calvin Knowlton | Medical data and medication selection and distribution system |
US7624029B1 (en) * | 2002-06-12 | 2009-11-24 | Anvita, Inc. | Computerized system and method for rapid data entry of past medical diagnoses |
US20040091909A1 (en) * | 2002-07-05 | 2004-05-13 | Huang Doug Hui | High throughput cytochrome P450 genotyping |
ES2575903T3 (es) * | 2003-02-20 | 2016-07-04 | Mayo Foundation For Medical Education And Research | Métodos para seleccionar medicamentos antidepresivos |
US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
US20040193446A1 (en) * | 2003-03-27 | 2004-09-30 | Mayer Steven Lloyd | System and method for managing a patient treatment program including a prescribed drug regimen |
US20050084880A1 (en) * | 2003-07-11 | 2005-04-21 | Ronald Duman | Systems and methods for diagnosing & treating psychological and behavioral conditions |
US20050037366A1 (en) * | 2003-08-14 | 2005-02-17 | Joseph Gut | Individual drug safety |
US20050069936A1 (en) * | 2003-09-26 | 2005-03-31 | Cornelius Diamond | Diagnostic markers of depression treatment and methods of use thereof |
DE10345837A1 (de) * | 2003-10-02 | 2005-04-21 | Bayer Technology Services Gmbh | Verfahren zur Bestimmung einer Wirkstoffdosierung |
WO2005038049A2 (en) * | 2003-10-06 | 2005-04-28 | Heinrich Guenther | System and method for optimizing drug therapy |
US7813880B2 (en) * | 2004-03-25 | 2010-10-12 | University Of Maryland, Baltimore | Apparatus and method for providing optimal concentrations for medication infusions |
US20080195326A1 (en) * | 2004-05-03 | 2008-08-14 | Martin Munzer | Method And System For Comprehensive Knowledge-Based Anonymous Testing And Reporting, And Providing Selective Access To Test Results And Report |
US20050260549A1 (en) * | 2004-05-19 | 2005-11-24 | Feierstein Roslyn E | Method of analyzing question responses to select among defined possibilities and means of accomplishing same |
US7546285B1 (en) * | 2004-09-24 | 2009-06-09 | Sprint Communications Company L.P. | System and method for scoring development concepts |
NZ556461A (en) * | 2004-12-21 | 2009-12-24 | Academia Sinica | Genetic variants of vkorc1 predicting warfarin sensitivity |
JP2008526249A (ja) | 2005-01-13 | 2008-07-24 | プロジェニカ・バイオファーマ・エス・アー | invitro遺伝子タイピングのための方法および製品 |
CA2608930A1 (en) * | 2005-06-14 | 2006-12-28 | Baxter International Inc. | Pharmaceutical formulations for minimizing drug-drug interactions |
CA2911569C (en) * | 2005-11-29 | 2019-11-26 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
-
2006
- 2006-11-28 CA CA2911569A patent/CA2911569C/en active Active
- 2006-11-28 EP EP20168461.0A patent/EP3703058A1/en not_active Withdrawn
- 2006-11-28 EP EP06838538A patent/EP1958111A4/en not_active Ceased
- 2006-11-28 DK DK11185491.5T patent/DK2508621T3/da active
- 2006-11-28 EP EP17154177.4A patent/EP3223182A1/en not_active Withdrawn
- 2006-11-28 EP EP11185491.5A patent/EP2508621B1/en not_active Not-in-force
- 2006-11-28 JP JP2008543404A patent/JP2009517186A/ja active Pending
- 2006-11-28 ES ES11185491.5T patent/ES2529211T3/es active Active
- 2006-11-28 CA CA3060475A patent/CA3060475A1/en not_active Abandoned
- 2006-11-28 WO PCT/US2006/045631 patent/WO2007064675A2/en active Application Filing
- 2006-11-28 CA CA2630604A patent/CA2630604C/en active Active
- 2006-11-28 US US12/085,606 patent/US8589175B2/en active Active
- 2006-11-28 AU AU2006320633A patent/AU2006320633A1/en not_active Abandoned
-
2012
- 2012-03-12 JP JP2012054497A patent/JP2012123837A/ja active Pending
- 2012-12-06 JP JP2012267276A patent/JP5567107B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-18 HK HK13103317.5A patent/HK1176093A1/xx not_active IP Right Cessation
- 2013-10-14 US US14/053,220 patent/US20150006190A9/en not_active Abandoned
-
2014
- 2014-04-11 JP JP2014082043A patent/JP5894213B2/ja not_active Expired - Fee Related
-
2016
- 2016-12-02 US US15/367,950 patent/US20170147779A1/en not_active Abandoned
-
2018
- 2018-03-22 HK HK18104016.2A patent/HK1244906A1/zh unknown
-
2020
- 2020-11-10 US US17/094,683 patent/US20210166820A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20210166820A1 (en) | 2021-06-03 |
US20150006190A9 (en) | 2015-01-01 |
JP2012123837A (ja) | 2012-06-28 |
CA2911569A1 (en) | 2007-06-07 |
HK1244906A1 (zh) | 2018-08-17 |
CA3060475A1 (en) | 2007-06-07 |
EP3223182A1 (en) | 2017-09-27 |
US20140046684A1 (en) | 2014-02-13 |
US8589175B2 (en) | 2013-11-19 |
CA2630604A1 (en) | 2007-06-07 |
HK1176093A1 (en) | 2013-07-19 |
US20170147779A1 (en) | 2017-05-25 |
JP2013059665A (ja) | 2013-04-04 |
ES2529211T3 (es) | 2015-02-18 |
JP5567107B2 (ja) | 2014-08-06 |
EP2508621B1 (en) | 2014-11-05 |
EP1958111A4 (en) | 2009-07-08 |
EP2508621A1 (en) | 2012-10-10 |
WO2007064675A3 (en) | 2008-11-20 |
EP3703058A1 (en) | 2020-09-02 |
AU2006320633A1 (en) | 2007-06-07 |
EP1958111A2 (en) | 2008-08-20 |
CA2630604C (en) | 2016-01-19 |
US20090171697A1 (en) | 2009-07-02 |
WO2007064675A2 (en) | 2007-06-07 |
JP2009517186A (ja) | 2009-04-30 |
JP2014176718A (ja) | 2014-09-25 |
CA2911569C (en) | 2019-11-26 |
JP5894213B2 (ja) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210166820A1 (en) | Optimization and individualization of medication selection and dosing | |
Karlsson Linnér et al. | Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences | |
Rieder et al. | Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | |
de Leon et al. | Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19 | |
Kusters et al. | Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease | |
Baye et al. | Mapping genes that predict treatment outcome in admixed populations | |
Wang et al. | Large-scale assessment of polyglutamine repeat expansions in Parkinson disease | |
Knisely et al. | CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids | |
MX2013012234A (es) | Sistema y metodos de prueba genetica para el control de peso. | |
Sombekke et al. | HLA-DRB1* 1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis | |
Reynolds et al. | Clinical utility and economic impact of CYP2D6 genotyping | |
AU2012203861B2 (en) | Optimization and individualization of medication selection and dosing | |
AU2020203492A1 (en) | Optimization and individualization of medication selection and dosing | |
Gorwood et al. | Introduction on psychopharmacogenetics | |
Mathew et al. | Dietitians’ and nutritionists’ knowledge of nutritional genomics and perception toward genetic testing for a personalized approach in noncommunicable diseases (NCDs) prevention and management in India: A cross-sectional survey | |
CA3205403A1 (en) | Systems and methods for providing medicine recommendations | |
WO2022131933A1 (en) | Systems and methods for providing medicine recommendations | |
JP2022181078A (ja) | 投与計画決定支援システム、投与計画決定支援方法、および投与計画決定支援プログラム | |
Kaur et al. | Systematic review into the role of genomics in profiling overall drug performance and variability. | |
Kim | Pharmacogenomics and pharmacologic class effect in drug safety management |